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Abstract
The development of effective treatments for opioid dependence is of great importance given the
devastating consequences of the disease. Pharmacotherapies for opioid addiction include opioid
agonists, partial agonists, opioid antagonists, and alpha-2-adrenergic agonists, which are targeted
toward either detoxification or long-term agonist maintenance. Agonist maintenance therapy is
currently the recommended treatment for opioid dependence due to its superior outcomes relative to
detoxification. Detoxification protocols have limited long term efficacy and patient discomfort
remains a significant therapy challenge. Buprenorphine’s effectiveness relative to methadone
remains a controversy and may be most appropriate for patients in need of low doses of agonist
treatment. Buprenorphine appears superior to alpha-2 agonists, however, and office-based treatment
with buprenorphine in the US is gaining support. Studies of sustained-release formulations of
naltrexone suggest improved effectiveness for retention and sustained abstinence, however,
randomized clinical trials are needed.
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1. OPIOID DEPENDENCE TREATMENT: OPTIONS IN PHARMACOTHERAPY
Annual prevalence estimates of heroin dependence in the USA remain stable at about 0.14%,
although some recent indicators suggest a decrease 1. In other countries prevalence rates are
higher, e.g., 2% of the population in South East and South West Asia are heroin dependent.
Prevalence of non-medical use of opioid pain relievers has increased significantly, with over
2 million people in the U.S. abusing prescription opioids 1. While these rates are low relative
to other substances of abuse, such as alcohol and marijuana, the burden of disease is substantial,
with high rates of morbidity and mortality, disease transmission, increased health care, crime
and law enforcement costs, and less tangible costs of family distress and lost productivity 2.
Clinically, there are two general treatment paths from which to choose, opioid maintenance
treatment or detoxification. Most opioid dependent individuals engage in both, likely multiple
times, during the course of their drug-using careers. Agonist and partial agonist medications
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are commonly utilized for both maintenance and detoxification purposes; alpha-2-adrenergic
agonist medications are primarily used to enhance detoxification outcomes. Antagonist
medications are used to accelerate the detoxification process and prescribed post-detoxification
to assist in preventing relapse. Success of the various treatment approaches and combinations
of treatments is assessed in a number of ways with the primary outcomes of interest being
retention in treatment, and opioid and other drug use. Secondarily, HIV risk behaviors, legal/
crime involvement, psychiatric symptoms, and morbidity are also used as indicators of
treatment success. With regard to detoxification, there are undoubtedly differences between
individuals withdrawing from illicit opioid use and those withdrawing from methadone or
buprenorphine maintenance and the contexts in which these occur, however, due to limited
prospective, comparative data this distinction is not highlighted for purposes of this review.
The review of pharmacotherapy options for opioid dependence derives from Medline, Pubmed,
and systematic reviews from the Cochrane Databases.
2. AGONIST MEDICATIONS FOR OPIOID DEPENDENCE
2.1. Methadone
Methadone is a full mu-opioid receptor agonist, typically used as a replacement therapy for
heroin or other opioid dependence. Methadone’s slow onset of action when taken orally and
long elimination half-life (24–36 hours) allows it to be used as either a maintenance therapy
or detoxification agent 3.
2.1.1. Maintenance—Methadone has been used as a substitution for heroin or other opiates
and, through the mechanisms of tolerance and cross-tolerance, prevents opioid intoxication
and withdrawal. Adequate dosing ranges from 80 – 150 mg, typically beginning with a daily
dose of 20–30 mg with increases of 5 or 10 mg until the optimal dose is reached. Methadone
maintenance treatment (MMT) is associated with retention in treatment, and reductions in IV
drug use, criminal activity, and HIV risk behaviors and mortality 4–7. It is currently the most
successful treatment for chronic opioid dependence, although not without fairly substantial
financial and personal costs to individuals participating in this therapy 8.
Several recent studies have found methadone to be associated with significant cardiac effects;
specifically, a prolonged QT interval in the ECG of methadone patients. One study found a
16.2% rate of QT prolongation in hospitalized methadone maintained patients compared to 0%
in non-methadone maintained, drug-injecting patients 9. Another study found that methadone
dose was related to a longer QT interval of .140 ms/mg in a cross-sectional study of daily
methadone users in free drug treatment clinics in Copenhagen 10. Thus, while patients in MMT
may need closer medical supervision than is currently in practice, methadone has been used
safely in the treatment opioid dependence for a number of years.
2.1.2. Detoxification—Methadone dose tapering or detoxification is controversial given the
relative effectiveness of MMT and the low rates of detoxification success 2. Regardless,
detoxification is an important component of any comprehensive opioid treatment program
11, particularly because the demand for methadone often outstrips community resources, at
least in the US. Wait-lists are long and patient financial constraints result in the premature
termination of a substantial number of patients by their opiate treatment providers. Effective
detoxification regimens are sorely needed.
Methadone dose reduction schedules have ranged from 2–3 weeks to as long as 180 days, with
longer time periods generally associated with better outcomes 12. Studies have indicated that
the more rapid the reduction, the worse the treatment retention and heroin use outcomes are,
although the optimal timeframe has yet to be clearly delineated 12, 13. There is some evidence
that higher doses of methadone are associated with more severe withdrawal symptoms during
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detoxification 14. A recent review of the evidence concludes that the use of long-acting opioids,
such as methadone, and slow tapering, accompanied by medical supervision, ancillary
medications, and psychosocial treatment can reduce withdrawal severity and improve
outcomes 2. Unfortunately, the vast majority of patients tend to relapse to heroin or other opiates
during or post-detoxification, which is not wholly surprising given the chronic and relapsing
nature of opioid dependence.
2.2. LAAM
Levomethadyl acetate or LAAM, a longer acting derivative of methadone and full mu-opioid
agonist substitute, was approved by the US Food and Drug Administration for maintenance
therapy in 1993. LAAM’s longer acting properties allow for thrice-weekly dosing--a
significant advantage over the required daily dosing of methadone. Oral LAAM typically is
administered on a Monday–Wednesday–Friday schedule starting at a daily 20 mg dose with
every other day increments to a maximum alternate day dosing of 130/130/180 or 100/100/140
15. As with methadone, stabilization doses vary widely across patients, ranging from 40 to 140
mg.
Several clinical trials comparing LAAM to methadone suggest LAAM to be at least comparable
and occasionally superior on primary outcomes such as retention in treatment and frequency
of opiate positive urine screens 15, 16. Regardless, LAAM was not embraced by opioid
treatment providers in the US, likely for varied and complex reasons 17. The most cited reason,
however, was concern over prolongation of the QT interval and report of several deaths in the
US and in Europe 18, 19. Although methadone has recently been associated with cardiac side
effects in some patients, and despite direct comparison data indicating few differences in
LAAM and methadone on cardiac measures, Roxane Laboratories has discontinued the sale
and distribution of LAAM. The well-established benefits of methadone and reluctance of opiate
treatment providers to shift to new treatment paradigms has reduced viable and perhaps
superior treatment options to the opiate dependent population.
3. PARTIAL AGONIST MEDICATIONS FOR OPIOID DEPENDENCE
3.1. Buprenorphine
In October of 2002, sublingual buprenorphine and buprenorphine/naloxone tablets for the
management of opiate dependence were approved by the FDA in the US. Prior to this time,
buprenorphine has been used successfully in many European countries as well as Australia
20, 21. Of significance in the US, buprenorphine is designated as a Schedule III drug making
it legal for qualified US physicians to prescribe it for opioid dependence. Unlike methadone
and LAAM which are full opioid agonists, buprenorphine is a partial agonist of mu-opioid
receptors. It has a slow onset and long duration of action allowing for alternate day dosing
22–24. Its partial agonist properties reduce the risk of unintentional overdose relative to full
agonist medications. The disadvantage, however, is that the partial agonism may also limit
buprenorphine’s maximum efficacy 25, 26. The recommended maximum sublingual dose is 24
or 32 mg which is equivalent to 60 to 70 mg of methadone. Many patients undergoing
methadone maintenance are on higher doses, with some on much higher doses (150+ mg).
Buprenorphine has also been combined with naloxone at a 4:1 ratio for the purpose of reducing
abuse liability. The 4:1 ratio was chosen based on results from several clinical pharmacology
studies 27–29 which suggested that this ratio results in negligible absorption of naloxone when
used sublingually, i.e., no significant withdrawal symptoms, but when crushed an injected, will
result in opioid receptor antagonism. Commercially available buprenorphine/naloxone is
typically either a 2/.5mg or 8/2mg combination; both of which are much lower than the
maximum dose and may limit the use of this product with patients at higher levels of opioid
dependence. More recent studies have suggested that 8/2 and 32/8 mg buprenorphine/naloxone
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are well-tolerated and more effective in reducing the reinforcing and subjective effects of
heroin, relative to the 2/0.5 mg dose 30.
3.1.1. Buprenorphine Maintenance—Outcome data from several studies have established
the superiority of buprenorphine maintenance over placebo 31–35. Results from studies
comparing buprenorphine and methadone, however, have been mixed, and dependent on
several factors such as dose level and flexibility 36–41. Overall, it appears that decreased illicit
opiate use and increased retention are seen with both higher doses of methadone (> 60 mg)
and higher doses of buprenorphine (> 8mg), although methadone appears superior to
buprenorphine in retaining patients when using flexible dosing approaches 30. There is some
evidence to suggest that inducting patients too slowly onto buprenorphine may contribute to
poorer retention rates 36, 42, however the lesser opioid effect and possibly mild withdrawal
symptoms when transferring from heroin to buprenorphine cannot be discounted. Also for
consideration, a meta-analysis by West et al. 41 indicated that buprenorphine tended to be more
effective in studies with patients who reported prior methadone maintenance experience vs.
studies that included subjects with no prior experience with methadone.
Given the mixed results regarding buprenorphine’s effectiveness relative to methadone,
controversy exists as to its role in the treatment of opioid dependence. Kakko et al. 43 suggest
a stepped care approach in which buprenorphine is the first-line treatment, with patients
escalated to methadone when needed. In a letter to the editor regarding Kakko and colleagues’
recommendation, Byrne and Wodak 44 claim that the data do not support buprenorphine as a
first-line treatment because almost two-thirds (65%) of their study patients were transferred to
methadone due to illicit drug use or cravings. Neither age, gender, duration of heroin use, nor
Addiction Severity Index aggregate scores predicted who stayed on buprenorphine/naloxone
vs. switched to methadone. Although much more research is needed to make definitive
conclusions, it has been recommended that higher dependence severity indicates placing
patients on the full agonist methadone over buprenorphine. However, it is unclear as to the best
way in which to measure dependence severity for this purpose. Researchers have suggested
that patients who require doses of more than 30–40 mg of methadone daily would be unlikely
to experience success with buprenorphine 25, 37. A subcutaneous buprenorphine implant has
also been tested, but no results have been published, and no studies are currently ongoing (Titan
Pharmaceuticals, 2008). Establishing effective buprenorphine regimens is an important
research goal, particularly in light of findings from a recent review which suggests a lower
mortality rate with buprenorphine relative to methadone maintenance 45. Further research is
needed to delineate patient and perhaps setting characteristics which indicate the prescribing
of one drug over the other.
3.1.2. Buprenorphine Detoxification—There is growing interest in using buprenorphine
as a way of managing opioid withdrawal. Because of the partial agonist properties,
buprenorphine is expected to produce fewer withdrawal symptoms as it is withdrawn, relative
to full agonist therapies 46. As with methadone, detoxification outcomes are likely dependent
on a complex interaction of factors including dependence severity, opioid used, dose taken,
duration of use, taper schedule, social/environmental circumstances, and psychological factors
such as fear of withdrawal, depression, and anxiety about life without drugs 47, 48, and to date
success rates have not been high. Gowing 49 reviewed 4 studies comparing the efficacy of
buprenorphine and methadone detoxification protocols 42, 50–52. Overall, the data suggest that
buprenorphine and methadone have similar efficacy for detoxification purposes, although
withdrawal via buprenorphine may be somewhat faster 53. Buprenorphine has repeatedly been
found superior to the alpha 2 adrenergic agonist clonidine in reducing symptoms of withdrawal,
retaining patients in a withdrawal protocol, and in treatment completion 54–58.
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Contrary to expectations, several studies found little difference in the severity of withdrawal
when tapering from buprenorphine compared to methadone 42, 51. However, the pattern of
withdrawal symptoms may indeed be different. Petitjean and colleagues 42 reported that while
patients withdrawing from methadone experienced a gradual increase in withdrawal symptoms
peaking at the end of the taper, buprenorphine patients reported higher withdrawal symptoms
earlier in the taper followed by a rapid decline. Similar findings were reported by Seifert 51.
Detoxification outcomes are possibly influenced by the rate of dose reduction, with several
studies suggesting that gradual tapering of buprenorphine results in higher completion rates
relative to rapid tapering 59, 60, and several studies indicating no reliable differences e.g., 61,
62. Many buprenorphine detoxification studies have been conducted on an inpatient basis and
were targeting withdrawal from heroin and not methadone. The extent to which results will
generalize to the outpatient setting and to methadone users is not fully known. Ling et al. 63,
however, conducted a multi-center randomized trial of buprenorphine-naloxone and found
superior results for buprenorphine in both the inpatient and outpatient arms relative to the
clonidine. Although retention rates were similar in the inpatient vs. outpatient settings, success
rates were about double for inpatients. Caution must be used in interpreting these data, however,
as patients were not randomly allocated to the two settings. The few studies of managed
methadone withdrawal using buprenorphine have reduced the methadone dose to 30 mg or less
prior to beginning buprenorphine and have delayed the first dose 24 hours after the last dose
of methadone 64, 65. The transition from methadone to buprenorphine has been found to
precipitate withdrawal 66, and must be approached carefully.
To date, buprenorphine has not surpassed methadone in its effectiveness for managed
withdrawal; however, there is significant potential. Additionally, there has been limited
research on post-detoxification outcomes leaving it unclear as to whether one medication is
superior to the other in the long-term 67. Much research is needed to identify the optimal
conditions under which buprenorphine can succeed for detoxification purposes, including
optimal duration, setting, route of administration, severity of dependence, and whether patients
are withdrawing from heroin vs. methadone.
3.1.3. Buprenorphine in the Primary Care Setting—In the US the ability of primary
care physicians to prescribe buprenorphine for opioid dependence presents an important and
far-reaching opportunity to improve access and quality of treatment as well as reduce social
harm. Positive effects have been documented in many countries. European, Asian, and
Australian data suggest that opioid related deaths and drug injection-related medical morbidity
have decreased with the introduction of buprenorphine. In France, national surveys conducted
annually in treatment facilities for drug dependent individuals suggested that widespread
initiation of office-based buprenorphine treatment in 1996 was associated with a decline of
heroin use among opiate users from 74% in 1995 to 25% in 1997, as well as with improvements
in the social and medical status of opioid dependent patients 68–70. Buprenorphine treatment
also has reduced various infectious diseases related to intravenous drug use 71, 72.
Following four initial US studies on buprenorphine effectiveness 58, 73–75, recent studies also
have supported office-based buprenorphine treatment efficacy by investigating longer
retention intervals and additional settings (See Table 1) 76–78. The 79% retention rate found
by Fiellin et al. 73 in a private office setting was followed by similar evidence from Cunningham
et al. 76 of 71% retention in an urban community health center setting. Buprenorphine is
effective for treatment of both injection and oral opioid users, but results have been mixed over
whether buprenorphine can be said to be clearly more successful for one particular route of
administration over another.
Some patients may desire to transfer from methadone to primary-care based buprenorphine
maintenance. At present, data regarding precipitation of withdrawal when switching from
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methadone or LAAM to buprenorphine are limited, particularly for doses of methadone over
30 mg daily. Additionally, buprenorphine is quite expensive relative to methadone, making it
available mainly to individuals with adequate resources.
4. ALPHA-2-ADRENERGIC AGONIST MEDICATIONS FOR OPIOID
DETOXIFICATION
Several alpha-2-adrenergic agonist medications have been investigated and found to facilitate
positive opioid withdrawal outcomes. One process underlying opioid withdrawal is
noradrenergic hyperactivity 79. Alpha-2-adrenergic agonists moderate the symptoms of
noradrenergic hyperactivity by acting centrally. Clonidine was the first alpha-2 agonist
discovered to ameliorate some signs and symptoms of withdrawal. Because it is not a drug of
abuse or dependence, clonidine has gained widespread use as a non-opioid alternative for
managing withdrawal 80. Unfortunately, clonidine is associated with significant hypotension
which has limited its use. This finding led to a search for alternative alpha-2 agonist medications
without significant side effects. Lofexidine, guanfacine, and guanabenz acetate have been
investigated to varying extents 81. Of these, lofexidine has been the most frequently studied
82–87, and results indicate it does not appear to have the hypotension side effect that plagues
clonidine. It is likely to replace clonidine as the leading opioid withdrawal treatment in this
drug class.
Initial studies of clonidine reported reduction or elimination of lacrimation, rhinorrhea, muscle
pain, joint pain, restlessness, and gastrointestinal symptoms 88, 89, suggesting significant
potential for managing opiate withdrawal. Clonidine is typically administered orally, in three
or four doses per day up to a maximum of one milligram per day. Dizziness, sedation, and
lethargy attributed to orthostatic hypotension and dry mouth were the primary adverse side
effects.
Lofexidine can be prescribed up to about two milligrams per day and appears to be associated
with fewer adverse effects. Completion rates of managed withdrawal assisted with clonidine
and other alpha-2-adrenergic agents vs. methadone have been comparable 90–92, with at least
one study finding poorer outcomes for clonidine 93. Withdrawal symptoms, while reasonably
similar in intensity demonstrate a difference in time course. Symptoms occur much earlier in
the withdrawal period for clonidine and lofexidine than for methadone, which perhaps has
implications for length of time in treatment. In a few studies specifically reporting duration of
treatment, subjects receiving reducing doses of methadone remained in treatment longer than
those receiving alpha-2 agonists 92, 94.
In the United Kingdom, lofexidine has had a product license for treatment of opiate
detoxification since 1992, and the extent of use has increased steadily since that time.
Lofexidine treatment is typically initiated at .2 mg twice daily, increasing daily by .2–.4 mg
with a recommended final dose of 2.4 mg/day. Doses required to effectively manage
withdrawal symptoms, however, vary for each patient depending on the amount, frequency,
and duration of opioid used. Yu et al. 87, in a phase 3 randomized, placebo-controlled trial,
confirmed that lofexidine significantly decreases the signs and symptoms of opioid withdrawal.
Retention was also higher in the lofexidine condition. Three studies comparing the efficacy
and tolerability of lofexidine to clonidine suggested comparable efficacy in reducing
withdrawal symptoms, with an advantage for lofexidine due to smaller hypotensive effect.
Interestingly, Bearn et al. 90 reported that an accelerated 5-day lofexidine regimen resulted in
faster attenuation of withdrawal symptoms relative to a more conventional 10-day lofexidine
schedule.
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As stated earlier, buprenorphine appears to be somewhat more effective in facilitating opioid
withdrawal than clonidine 63, 95. Of the two open-label trials comparing lofexidine and
buprenorphine, one found the two treatments to be equivalent in effectiveness 84, while the
other found buprenorphine to result in less severe withdrawal symptoms in a large portion of
subjects 86. Thus, the alpha-2-adrenergic agonists are of significance given the paucity of
medications approved for opioid detoxification and relapse prevention purposes, particularly
non-opioid medications; arguably, however, alpha-2 agonists may not be the best “first-line”
treatment for opioid detoxification. Further research is needed to determine optimal dose,
duration and perhaps combinations of medications to improve upon the typically poor
detoxification outcomes.
5. ANTAGONIST MEDICATIONS FOR OPIOID DEPENDENCE
Naltrexone is an oral, long-acting, opioid antagonist with high affinity to mu-opioid receptors.
A daily dose of naltrexone (50 mg) will block the pharmacologic effects of 25 mg IV heroin
for as long as 24 hours, and increasing the dose extends its duration of action to 48 hours with
100 mg and 72 hours with 150 mg 96. Neither tolerance nor dependence develops with
naltrexone 97, 98. Oral naltrexone is approved for relapse prevention of alcohol and opioid
dependence in several countries, although its effectiveness for the latter remains in question
99.
In general, clinical research on naltrexone over the past few decades indicates that it is safe,
associated with few side effects, and clearly blocks the reinforcing properties of heroin and
other opiates. Original fears that naltrexone would cause hepatotoxicity or elevate liver
function tests appear unwarranted 100–102. It remains common practice, however, to evaluate
liver function prior to administering naltrexone and refrain from prescribing if liver function
tests are 3–5 times normal levels. Failure to prescribe naltrexone to patients with less elevation
in LFTs is unfortunate as a significant proportion of the opiate-using population has liver
disease, e.g., Hepatitis B or C 103, 104. Naltrexone has in fact been associated with
improvements in LFTs due to reductions in alcohol/opiate use 105, 106. Further, naltrexone has
few additional side effects. The most commonly reported symptoms are headache, nausea,
abdominal pain, as well as dysphoria, and depression in a subgroup of patients 107, 108.
Although naltrexone has theoretically ideal properties, only weak support exists for its
effectiveness in clinical settings. A recent meta-analysis 99 reviewing 10 studies (N = 696)
concluded that naltrexone maintenance combined with psychosocial therapy was, in fact, more
effective than placebo in reducing heroin use and re-incarceration rates during treatment.
However, results of studies using naltrexone alone did not differ from placebo, and, in the
majority of studies, retention, side effects and relapse rates were all similar to placebo. Most
researchers would agree and there is data 109 demonstrating that the primary problem with
naltrexone is low adherence to the medication and poor retention in treatment. Presumably
because naltrexone has no reinforcing properties of its own, blocks reinforcement from
occasional lapse to opiates, and has no associated withdrawal syndrome encouraging its
continued use, acceptance of the treatment by patients is low relative to agonist-based
treatments. Many studies have reported large numbers of dropouts in the first few weeks of
treatment, with those lapsing to opiate use after missing naltrexone doses especially likely to
dropout 110. For example, Rothenberg 111 reported that only slightly more than half of
participants completed 4 weeks of a 24 week naltrexone-behavior therapy protocol. Greenstein
et al. 112 reported that 47% of opiate dependent patients dropped out of treatment in the first
few weeks. Further, Tennant et al. 113 reported over a quarter of their patients dropped out after
only a few days. Rothenberg 111 also reported even lower retention for patients using
methadone at baseline —39% completed 1 month and no patients completed the full 6-months
of treatment. These data suggest that transition from long-acting opioids to naltrexone may be
Stotts et al. Page 7
Expert Opin Pharmacother. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
especially difficult and portend the need for improved methods for transitioning to antagonist
treatment.
5.1. Sustained-Release Formulations of Naltrexone
Due to poor rates of adherence 109, sustained release formulations of naltrexone are being
developed in hopes of improving outcomes, and are currently the focus of much research.
Although 9 different sustained-release formulations are available, none is approved for opioid
dependence in the US, Europe or Australia. Three depot injection formulations are being
investigated and deliver therapeutic doses (blood levels between 1–2 ng/ml) for up to 4 weeks
114, 115. Comer et al. 116 has conducted the only published, randomized, controlled clinical
trial investigating injectable, sustained release naltrexone in 60 heroin dependent patients.
Following an initial inpatient detoxification and 3 consecutive days of oral naltrexone, patients
were randomized to receive placebo, 192 or 384 mg of depot naltrexone (Depotrex; BIOTEK,
Inc, Woburn, MA). A second injection of the same dose was administered after week 4 of the
8 week study. Retention in treatment was superior for the two naltrexone conditions (60 and
68% remaining at end of study in the 192 and 384mg groups, respectively) relative to placebo
(39% remaining). A significant dose response relationship was found on time to dropout, with
the higher naltrexone group remaining in treatment the longest. Significant effects on opiate
use across the study were also found, favoring the naltrexone groups over placebo. Treatment-
related side effects were relatively mild (e.g., fatigue, injections site induration, and injection
site pain), although 5 participants (1 in placebo and 4 in the 192 mg groups) were discharged
from the study for injection site redness or induration. Injection site problems have been
reported in other studies of alcohol and opioid dependent patients, and found at significantly
greater frequency with naltrexone relative to placebo 117–119.
Although it is premature to conclude sufficient effectiveness, sustained release depot
naltrexone formulations appear to hold significant promise in improving retention, and
presumably decreasing opiate use in opioid dependent patients.
Subcutaneous naltrexone implants are also being used in the treatment of opioid dependence,
particularly in Russia and China. Data on implants of 1.1, 2.2, and 3.3 g naltrexone have been
reported. A recent study by Ngo et al. 120 concluded that a 3.3 g implant provided longer
therapeutic coverage compared to the 1.1g implant, but was not significantly different from
the 2.2 g implant. The primary difficulty in evaluating the effectiveness of sustained-release
naltrexone is the lack of clinical trials, although a clinical trial has been presented showing
superior treatment retention with a naltrexone implant compared to oral naltrexone and a
placebo implant (College on Problems of Drug Dependence, June 2007, Quebec City, Canada).
In that study 190 detoxified opiate addicts were randomized to the three treatment groups, and
at the end of six months 45% of patients of the naltrexone implant group had relapsed compared
to about 85% in the other two groups (p<0.001). Cohort studies have been reported and results
are quite favorable. For example, Foster et al. 121 reported 74–79% opiate abstinence rates 12
weeks after implantation. Fifteen percent had local tissue reactions that were mild with no
regional lymphadenopathy, resolving without surgical treatment.
Recent reports of serious adverse events associated with naltrexone implants have surfaced,
however. A retrospective chart review of ER patients referred to Drug and Alcohol
Consultation-Liaison services in 2 teaching hospitals in Sydney, Australia reported 12 patient
admissions in a one-year period with implant-related presentations 122. Six of 12 admissions
were for severe dehydration and opiate withdrawal secondary to rapid opioid detoxification
and naltrexone implantation in the prior 24–48 hours. Opioid overdose deaths have also been
reported 123. Conversely, longitudinal cohort data collected prospectively in Australia indicate
an absence of mortality associated with naltrexone implant treatment 124, and further,
naltrexone implantation has been associated with long-term reductions in opioid-related
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hospital morbidity 125. Davoli et al. 126 report that overall, overdose mortality risk while in
opioid treatment is significantly lower than when out of treatment, with the first month post-
treatment being a considerably risky time. Thus, although more research is needed, initial data
on naltrexone implants indicate significant improvements in adherence and retention, and
perhaps increased effectiveness for relapse prevention. Careful participant selection and close
clinical management is clearly warranted, however, to prevent serious adverse outcomes.
5.2 Rapid and Ultra-Rapid Opiate Detoxification
While gradual dose reduction of methadone or buprenorphine is perhaps the most
straightforward way in which to manage opiate detoxification, this method is time-consuming
and plagued by high dropout rates. Alpha 2 adrenergic agonists, such as clonidine and
lofexidine, assist in reducing some of the symptoms of opiate withdrawal, however, they do
not alter the duration of withdrawal 127. Use of the opioid antagonist naltrexone, typically
combined with an alpha 2 adrenergic agonist, has been investigated as a method for rapid opiate
detoxification (ROD) and has been purported to shorten the duration of withdrawal without
significantly increasing patient discomfort128. Another benefit to ROD is the reduced time
between opioid use and the commencement of naltrexone treatment. Controlled studies
comparing naltrexone plus clonidine to clonidine alone or to methadone tapering have found
that the former approach was well tolerated and reduced the withdrawal period while improving
retention 13, 58, 129, 130. ROD completion rates using naltrexone and clonidine range from
75%–81% compared to 40–65% for methadone or clonidine alone 58, 131. Lofexidine has been
shown to have equal efficacy with clonidine when combined with naltrexone and has fewer
side effects 132, perhaps making it a more suitable detoxification medication, particularly in
outpatient settings. Gowing and Ali 11, however, based on their review of 7 studies, report that
it is still unclear whether withdrawal induced by opioid antagonists in combination with
adrenergic agonists actually facilitates the transfer to sustained naltrexone treatment beyond
10 to 14 days, and thereby improving effectiveness, relative to adrenergic agonists alone.
Buprenorphine and methadone have also been used in combination with naltrexone. Umbricht
et al. 133 stabilized patients on buprenorphine prior to detoxification with naltrexone and
clonidine and found the treatment to be safe with an even shorter duration of detoxification
relative to patients stabilized on methadone or using heroin (one day vs. three days of
detoxification). Gerra et al. 134 conducted an observational study suggesting potential benefit
from the combination of lower doses of buprenorphine (4 mg) and naltrexone as a detoxification
and subsequent maintenance strategy to counteract the protracted opioid abstinence syndrome
common after detoxification, i.e., dysphoria and somatic symptoms. Another uncontrolled
study of 3-day ROD using one dose of 50 mg naltrexone with methadone maintenance patients
reported a shortened withdrawal syndrome (managed by symptom-relief meds) 135. Two-
phases of symptoms were reported: (1) a first withdrawal phase, seen in most patients,
characterized by common symptoms and likely naltrexone-induced; and (2) a second phase
experienced by fewer patients (aches, insomnia and loss of appetite worsened) and likely
attributed to declining methadone concentrations.
Ultra-rapid opiate detoxification (UROD) is an extension of ROD with the use of anesthetics.
UROD is highly controversial due to the medical risks and mortality associated with anesthesia
relative to the painful, yet non-fatal risks of untreated opiate withdrawal. At least one death
during the recovery period of this intervention has been reported 136. Further, while withdrawal
severity following anesthesia-assisted withdrawal did not differ, Collins et al. 137 reported three
life-threatening adverse events in the anesthesia group, but none in the buprenorphine or
clonidine groups. Effectiveness relative to alternative detoxification procedures is difficult to
evaluate as most studies have not included longer term follow-up data or randomization to a
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comparison condition. Some studies report relatively high rates of abstinence 138, 139 while
others report worse outcomes with UROD 140.
In sum, ROD with naltrexone and clonidine is safe and effective in the management of opiate
withdrawal. While the duration of detoxification is shortened, effectiveness in facilitating
continued use of antagonist treatments post-detoxification has yet to be established. UROD
remains controversial with regard to safety and is also quite expensive, thus significantly
limiting its use.
6. CONCLUSION
Given the burden of disease, the development of effective treatments for opioid dependence is
of great significance. Methadone maintenance is currently the gold standard of treatments as
it is associated with reductions in intravenous drug use, crime, HIV risk behaviors and
mortality, and is well-established in community treatment programs around the world. New
and evolving opioid treatments are held to this standard. Yet even when comparing favorably
to methadone (e.g., LAAM), new pharmacotherapies may be viewed with reluctance, which
can have the untoward effect of prematurely limiting use and availability. Cardiac side effects
have been documented for both LAAM and methadone, though, and patients should be
carefully monitored for such. In recent years, buprenorphine has emerged as a potential first-
line treatment for opioid dependence and may be ideal for patients needing lower doses of
agonist medications. Buprenorphine has a reduced risk of overdose relative to full agonist
therapies, and in combination with naloxone, has reduced abuse liability. Office-based
buprenorphine treatment has the potential to expand the reach of opioid treatment thereby
improving the social and medical status of increasing numbers of opioid dependent patients.
Further research is needed to identify patient and setting characteristics best suited for
buprenorphine vs. methadone.
Opioid detoxification remains a critical area of focus. There is no consensus on the most
effective pharmacological strategy to achieve complete abstinence from all opiates. Relapse
either during or after detoxification occurs in the majority of patients, and, for those who have
the resources, return to maintenance treatment is common. Despite the dismal rates of success,
a minority of patients are able to detoxify successfully from methadone, heroin and other
opiates. Research has yet to determine, however, who will succeed and who will fail. In a recent
manuscript reporting on a 6-month LAAM detoxification study in which almost every
participant returned to opioid use (methadone maintenance or illicit opioids), Grabowski et al.
(under review) concluded that neither patients nor clinical researchers are adequately equipped
to determine a patient’s preparedness for complete withdrawal141. For these reasons, experts
understandably have recommended agonist maintenance treatment over detoxification.
However, long-term methadone maintenance treatment is not without adverse consequences.
Methadone like other opioids produces sustained constipation in some individuals which if left
untreated can lead to toxic megacolon. The only fatalities from methadone unrelated to
overdose have been caused by this side effect. Methadone also elevates serum prolactin and
lowers testosterone levels which can impair sexual functioning. Further, under many
circumstances, such as lack of financial resources to initiate or continue maintenance treatment,
detoxification of opioid dependent patients is essential. Thousands of patients each year (at
least in the US) are terminated from opiate treatment programs for failure to pay and other
“non-therapeutic” reasons 142. Without effective detoxification protocols, individuals lacking
resources will inevitably continue or return to illicit opiate use and, consequently, the myriad
of associated psychosocial and health problems.
Various pharmacotherapies and dose reduction protocols have been tested to improve
detoxification outcomes. Alpha 2 adrenergic agonist medications, such as clonidine and
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lofexidine, have gained widespread use because they are a non-opioid alternative. Their
effectiveness as single agents is inferior to managed withdrawal using buprenorphine, however,
they have had more patient acceptance as adjunctive agents during buprenorphine tapering.
Naltrexone, a long-acting opioid antagonist seems an ideal candidate medication for prevention
of relapse to opiates, but is associated with unacceptably low adherence and retention rates.
Sustained-release formulations have been developed with strong support for naltrexone
implants from mostly uncontrolled studies, although questions regarding safety have yet to be
answered. Further research attending to issues of both efficacy and safety is needed to
rigorously test this promising treatment.
7. EXPERT OPINION
Opioid pharmacotherapy faces a significant challenge because the most rapidly growing
populations needing treatment in the United States are adolescents and young adults.
Prescription opioids have become the most commonly abused illicit drug during the last 5 years
among these young abusers 1, 143. In the treatment of young abusers, it is necessary to recognize
that developmental processes are ongoing and hormone levels are changing and influencing
growth in many organs, including the brain. This developmental perspective must inform any
pharmacotherapy decision, and a decision to simply provide withdrawal treatment and no
ongoing relapse prevention treatment is simply untenable in this era of infectious diseases such
as HIV and hepatitis C which are frequent comorbidities of opioid abuse and dependence
144.
Chronic opioid agonist treatments are the gold standards for efficacy, but providers and parents
have significant reluctance to enroll adolescents in a sustained program of maintenance on
methadone, and the usual treatment for opioid-addicted youth is detoxification and counseling.
Extended medication-assisted therapy may be more helpful, and a different attitude may be
developing for buprenorphine, particularly as an office-based therapy. A recent study at six
community programs evaluated the efficacy of continuing buprenorphine-naloxone for 12
weeks vs. detoxification for opioid-addicted youth 145. They enrolled 152 patients aged 15 to
21 years who were randomized to 12 weeks of buprenorphine or a 14-day taper detoxification.
The patients in the detoxification group had higher proportions of opioid-positive urine tests
at weeks 4 and 8, and by week 12, only 21% remained in treatment compared to 70% of those
maintained on buprenorphine. Thus, continuing treatment with buprenorphine improved
outcome compared with short-term detoxification, which encourages further research into the
efficacy and safety of longer-term treatment with buprenorphine for young individuals with
opioid dependence.
The antagonist naltrexone seems an ideal treatment for these reluctant young patients, since
we have developed long lasting depot formulations such as Vivitrol and naltrexone implants
that can overcome these patients’ poor adherence to taking daily medications 116, 117, 121.
Starting naltrexone requires initial withdrawal treatment, however, and our treatments have
had limited efficacy using clonidine. Lofexidine availability in the US is expected to improve
upon clonidine-assisted withdrawal treatments, as it has in many European countries.
Lofexidine may have a second important role during naltrexone maintenance as stress-induced
relapse may be reduced by several months of sustained treatment with lofexidine after
detoxification is completed. Nevertheless, a problem for commercial depot naltrexone products
such as Vivitrol is that its FDA approval is limited to alcoholism, thereby making its use for
opioid dependence “off label” and potentially a medical and economic risk. The economic risk
is that depot naltrexone is relatively expensive at about five times the cost of oral naltrexone.
Since opioid dependence is not an approved FDA indication, insurance carriers may not
reimburse its substantial cost of about $10,000 for a year’s treatment. The medical risk involves
these antagonists’ significant hormonal effects on increasing cortisol, growth hormone,
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lutenizing and follicle stimulating hormones (LH and FSH) 146. The unintended consequences
of these hormonal perturbations range from growth retardation and affective instability to
increased fertility in adolescent girls leading to pregnancy when effective birth control is not
used. In summary, current pharmacotherapies have great potential, but have associated risks
in our growing population of young opioid abusers.
A very attractive, more cost-effective alternative has been potential therapeutic vaccination or
even monoclonal immunotherapy 147. These immunotherapies are very appealing because they
have no direct effects on the brain, endocrine system or any other organs. Their mechanism of
action is simply that the anti-opioid antibody binds to the abused opioid and thereby holds the
opioid in the blood stream preventing its entry into any of these organs 148. As this opioid-
antibody complex passes through the liver, the opioid is extracted and converted into inactive
metabolites that are then excreted in the bile and kidney. Vaccination-induced antibody levels
remain high enough to block a specific opiate for about 8–12 weeks after which a booster is
needed to get the antibody levels back for 2–3 months. This vaccine approach has been quite
feasible for both nicotine and cocaine in human vaccines 147, 149. A significant challenge to
this approach has been the wide range of abused prescription opioids. Because antibodies are
highly specific for the chemical structures of the various opioids, an antibody to morphine will
not be effective for oxycodone or codeine or fentanyl or many other abused opioids. Making
vaccines or monoclonal antibodies to the wide range of opioids is possible, but a logistic
challenge that seems still more than 5 years in the future as we understand how to provoke
stronger immune responses to haptens like these drugs and to produce monoclonals more cost-
effectively. Thus, new options are evolving in pharmacotherapy of opioid dependence, and the
increased safety and efficacy of these options will be particularly important as we target these
abusers early in their addiction careers in order to avoid the major life-threatening
complications that arise from sustained abuse of these drugs.
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